Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Iradimed (IRMD) Net Margin (2016 - 2025)

Iradimed (IRMD) has disclosed Net Margin for 13 consecutive years, with 26.3% as the latest value for Q3 2025.

  • On a quarterly basis, Net Margin fell 125.0% to 26.3% in Q3 2025 year-over-year; TTM through Sep 2025 was 25.45%, a 68.0% decrease, with the full-year FY2024 number at 25.31%, down 92.0% from a year prior.
  • Net Margin was 26.3% for Q3 2025 at Iradimed, down from 28.29% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 32.79% in Q4 2021 to a low of 14.98% in Q2 2021.
  • A 5-year average of 24.6% and a median of 25.48% in 2022 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: skyrocketed 4607bps in 2021, then plummeted -764bps in 2022.
  • Iradimed's Net Margin stood at 32.79% in 2021, then fell by -23bps to 25.15% in 2022, then increased by 3bps to 26.01% in 2023, then fell by -12bps to 22.95% in 2024, then rose by 15bps to 26.3% in 2025.
  • Per Business Quant, the three most recent readings for IRMD's Net Margin are 26.3% (Q3 2025), 28.29% (Q2 2025), and 24.02% (Q1 2025).